Outcomes on anti‐VEGFR‐2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma

Overview of attention for article published in International Journal of Cancer, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

policy: 1 policy source

twitter: 39 X users

Readers on

mendeley: 21 Mendeley

So far, Altmetric has seen 57 X posts from 39 X users, with an upper bound of 188,409 followers.

RT @TumorBoardTues: 6/9 #TumorBoardTuesday Thurs Case🎀 Anticipate tumor evolution! 2L strat: 🌈trial ramucirimab + paclitaxel. 🐏+tax= ⬆️OS…

6/9 #TumorBoardTuesday Thurs Case🎀 Anticipate tumor evolution! 2L strat: 🌈trial ramucirimab + paclitaxel. 🐏+tax= ⬆️OS by 2 mos. Every gain (without sig added tox) counts! ✅Pre-tx w anti-PD-1 ⬆️ RR to 🐏+ tax. Case for FOLFOX + nivo upfront? https:…

RT @ShimaghavimiMD: @doctorC369 @MPishvaian @TumorBoardTues @HaeseongPark1 @NataliyaUboha @LizzySmyth1 https://t.co/k8RPK6tPMN

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 53 additional X posts.